Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.04.2015 | short review

Optimal follow-up of ovarian cancer patients

verfasst von: Eduard Vrdoljak, MD, PhD, Branka Petrić Miše, MD, Tihana Boraska Jelavić, MD, PhD, Snježana Tomić, MD, PhD, Dinka Šundov, MD, PhD, Ante Strikić, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Gynecological malignancies account for roughly 10 % of all cancers in women with ovarian cancer as leading cause of death due to gynecological tumors. Surveillance programs of ovarian cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for cure of patient with recurrence. Since there is no prospective, high evidence data on optimal surveillance program after primary treatment of patients with ovarian cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including gynecological examination, still contribute to the greatest number of recurrence detections. Radiologic and laboratory tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.
Vorheriger Artikel A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
Nächster Artikel Optimal follow-up of endometrial cancer patients
Literatur
1.
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed: 6 July 2014.
2.
Salani R, Backes FJ, Fung Kee Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignances: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78. doi:10.1016/j.ajog.2011.03.008.CrossRefPubMed
3.
Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol. 2009;71(1):43–52. doi:10.1016/jcritrevonc.2008.12.008.CrossRefPubMed
4.
5.
Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: resent advances. Hum Pathol. 2009;40(9):1213–23. doi:10.1016/j.humpath.2009.04.017.CrossRefPubMed
6.
Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6:201. doi:10.1186/1471-2407-6-201.CrossRefPubMedCentralPubMed
7.
8.
Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;102(3):432–9.CrossRefPubMed
9.
Armstrong DK, Bundy B, Wenzel L, et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.CrossRefPubMed
10.
Trimbos JB, Parmar M, Vergote I, et al. International Collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trial of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2);105–112.CrossRefPubMed
11.
Gadducci A, Cosio A, Zola P, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicentre retrospective Italian study. Gynecol Oncol. 2010;116(3):358–63. doi:10.1016/j.ygyno.2009.11.008.CrossRefPubMed
12.
Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):307–11. doi:10.1016/j.ygyno.2009.10.074.CrossRefPubMed
13.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.CrossRefPubMed
14.
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200.CrossRefPubMed
15.
Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegyleted liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628–35. doi:10.1200/JCO.2010.33.8566.CrossRefPubMed
16.
Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25. doi:10.1200/JCO.2008.19.1684.CrossRefPubMedCentralPubMed
17.
Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374(9698):1331–8. doi:10.1016/S0140–6736(09)61157–0.CrossRefPubMed
18.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.CrossRefPubMed
19.
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. doi:10.1056/NEJMoa1103799.CrossRefPubMed
20.
Kim A, Ueda Y, Naka T, et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14. doi:10.1186/1756–9966-31–14.CrossRefPubMedCentralPubMed
21.
Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.CrossRefPubMedCentralPubMed
22.
Palmar MK, Ledermann JA, Columbo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.3 trial. Lancet. 2003;361(9375):2099–106.CrossRef
23.
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.CrossRefPubMed
24.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–9. doi:10.1200/JCO.2009.25.7519.25.CrossRefPubMed
25.
Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study od recurrent and refractory ovarian cancer. Gynecol Oncol. 2004;95(1):1–8.CrossRefPubMed
26.
Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. doi:10.1200/JCO.2007.13.6606.CrossRefPubMed
27.
Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer study group. J Clin Oncol. 2011;29(2):242–8. doi:10.1200/JCO.2009.27.8911.CrossRefPubMed
28.
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. doi:10.1200/JCO.2013.51.4489.CrossRefPubMed
29.
Greer BE, Bundy BN, Ozols RF, et al. Implication of second-look laparotomy in the context of optimally resected stage II ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;99(1):71–9.CrossRefPubMed
30.
31.
Santillan A, Gary R, Zuhurak ML, et al. Risk of epithelial ovarian cancer recurrence in patient with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23(36);9338–43.CrossRefPubMed
32.
Piovano E, Attamente L, Macchi C, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359–65. doi:10.1097/IGC.0000000000000218.CrossRefPubMed
33.
Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19(3):367–74. doi:10.1111/IGC.0b013e3181a1cc02.CrossRefPubMed
34.
Rustin GJ, van der Burg ME, Griffin C. Early versus delayed treatment of relapsed ovarian cancer (MRC ov05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63. doi:10.1016/S0140-6736(10)61268-8.CrossRefPubMed
35.
Rustin GJ. Follow-up with CA 125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011;22(8):viii45–8. doi:10.1093/annonc/mdr471.
36.
Wang F, Ye Y, Xu X, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreductive surgery. J Ovarian Res. 2013;6(1):14. doi:10.1186/1757–2215-6–14.CrossRefPubMedCentralPubMed
37.
Xu X, Chen X, Dai Z, et al. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. J Exp Clin Cancer Res. 2013;32:61. doi:10.1186/1756-9966-32-61.CrossRefPubMedCentralPubMed
38.
Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117(2):336–40. doi:10.1016/j.ygyno.2010.01.014.CrossRefPubMed
39.
40.
Fehm T, Heller F, Krämer S, et al. Evaluation of CA 125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25(3 A):1551–4.PubMed
41.
Bhosale P, Peungjesada S, Wei W, et al Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA 125 levels. Int J Gynecol Cancer. 2010;20(6):936–44. doi:10.1111/IGC.0b013e3181e82a7f.CrossRefPubMed
42.
Risum S, Hogdall C, Markova E, et al. Influence of 2-(18 F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009;19(4):600–4. doi:10.1111/IGL.0b013e3181e3cc94.CrossRefPubMed
43.
Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT scan in suspected recurrent ovarian cancer: a prospective multicentre study as part of the Australian PET Date Collection Project. Gynecol Oncol. 2009;112(2):462–8. doi:10.1016/j.gyno.2008.08.027.CrossRefPubMed
44.
Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164–74. doi:10.1016/j.ejrad.2008.02.019.CrossRefPubMed
45.
Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24 (Suppl 6):vi24–32.PubMed
46.
Matkovic´ V, Haller H, Vrdoljak E, et al. [Clinical recommendations for diagnosing, treatment and monitoring of patients with ovarian cancer—Croatian Oncology Society and Croatian Society for Gynecology and Obstetrics as Croatian Medical Association units and Croatian Society of Gynecological Oncology]. Lijec Vjesn. 2013;135(9–10):235–41.PubMed
Metadaten
Titel
Optimal follow-up of ovarian cancer patients
verfasst von
Eduard Vrdoljak, MD, PhD
Branka Petrić Miše, MD
Tihana Boraska Jelavić, MD, PhD
Snježana Tomić, MD, PhD
Dinka Šundov, MD, PhD
Ante Strikić, MD
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0188-y

Weitere Artikel der Ausgabe 1/2015

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

  • short review

To maintain or not to maintain: treatment forever in myeloma?

  • short review

Tailoring treatment in myeloma: are there clues from biology?

  • short review

Predicting drug sensitivity by 3D cell culture models

  • review

Optimal follow-up of endometrial cancer patients

  • short review

Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients

  • short review